Anika Therapeutics | ANIK - Equity Capital And Reserves


Anika Therapeutics reported $137.28M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
Agenus USD -199.08M 22.15M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
Enanta Pharmaceuticals USD 126.59M 61.87M Dec/2025
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
Heron Therapeutics USD 6.91M 2.23M Jun/2026
Insmed USD 757.49M 52.64M Jun/2026
Integra LifeSciences USD 1.04B 971K Jun/2026
Intrexon USD 43.17M 75.33M Jun/2024
J&J USD 84.97B 3.78B Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Ligand Pharmaceuticals USD 967.52M 29.81M Jun/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merit Medical Systems USD 1.68B 53.08M Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sanofi EUR 69.57B 3.24B Jun/2026
Smith & Nephew USD 5.18B 356M Jun/2026
Stryker USD 22.98B 559M Mar/2026
Veracyte USD 1.39B 44M Jun/2026
Xencor USD 503.23M 12.4M Jun/2026
Zimmer Biomet Holdings USD 12.63B 49.1M Jun/2026